Last edition
News about
New HS 2028 Customs Codes to Boost Global Monitoring of Vaccines and Medical Supplies
The World Health Organization, working in collaboration with the World Trade Organization and the World Customs Organization, has supported an update to the global customs classification system to improve tracking and movement of vaccines and essential medical products.
US FDA Grants Orphan Drug Designation to IFx-2.0 of TuHURA Biosciences
TuHURA Biosciences has received FDA Orphan Drug Designation for IFx-2.0 to treat stage IIB–IV cutaneous melanoma, based on data from its completed Phase I study published in Molecular Therapeutics.
CHMP Recommends Imfinzi for Early Gastric Cancers
The EU’s CHMP has recommended approval of AstraZeneca’s Imfinzi perioperative regimen for early gastric and gastroesophageal cancers following positive phase-III MATTERHORN data, showing a 29 percent reduction in progression or recurrence risk and a 22 percent reduction in mortality versus chemotherapy alone.
Tenacia and Golden Age Health Partner to Commercialise Ztalmy for CDKL5 Deficiency Disorder in China
Tenacia Biopharmaceuticals has granted Golden Age Health exclusive rights to commercialise Ztalmy, the first approved therapy for CDKL5 deficiency disorder, in Mainland China.
Government Imposes Minimum Import Price on Key Antibiotic APIs to Support Domestic Manufacturing
The Union Ministry of Commerce and Industry has imposed a Minimum Import Price (MIP) on three key active pharmaceutical ingredients—penicillin and its salts, amoxycillin and its salts, and 6-aminopenicillanic acid (6-APA)—for a period of one year.
Piramal Pharma Solutions Commercialises Tablet-in-Capsule Technology at Indian Manufacturing Sites
Piramal Pharma Solutions has successfully developed and commercialised a tablet-in-capsule drug delivery system in India, enabling flexible dosing, dual-release profiles and improved patient-centric oral therapies.
Avidity Biosciences Sets Record Date for Atrium Therapeutics Spin Off Ahead of Novartis Merger
Avidity Biosciences announces February 12, 2026 as the record date for distributing Atrium Therapeutics shares to stockholders as part of its planned Novartis acquisition and cardiology spin-off.
SanegeneBio Announces RNAi Global Licensing Collaboration with Genentech
SanegeneBio has licensed one of its RNAi programmes to Genentech in a global collaboration valued at up to USD 1.7 billion, including a USD 200 million upfront payment, milestone-based development and commercialisation payments, and tiered royalties. Genentech will oversee worldwide clinical development and commercialisation.
WuXi Biologics and Vertex Pharmaceuticals collaborate to advance a preclinical trispecific T-cell engager targeting B-cell mediated autoimmune diseases under a global licensing agreement.
USPTO Issues New Patent to Acurx for DNA Polymerase IIIC Inhibitor Technology
The newly granted patent covers DNA polymerase IIIC inhibitors, including compositions of matter, methods of use and pharmaceutical formulations, further strengthening Acurx’s Intellectual Property (IP) portfolio and expanding its growing patent estate in the US and international markets.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy